WallStreetZenWallStreetZen

NYSEMKT: CLDI
Calidi Biotherapeutics Inc Stock

$2.13-0.19 (-8.19%)
Updated Dec 8, 2023
CLDI Price
$2.13
Fair Value Price
N/A
Market Cap
$75.48M
52 Week Low
$1.50
52 Week High
$13.79
P/E
-0.78x
P/B
-68.99x
P/S
1,057.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$45.00k
Earnings
-$52.53M
Gross Margin
68.9%
Operating Margin
-114,392.58%
Profit Margin
-116,735.5%
Debt to Equity
-17.99
Operating Cash Flow
-$34M
Beta
-0.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CLDI Overview

First Light Acquisition Group, Inc. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets companies that provide technology-enabled solutions with high-growth, mission-critical applications in government and commercial markets. First Light Acquisition was incorporated in 2021 and is headquartered in Reston, VA.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLDI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CLDI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CLDI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CLDI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more CLDI due diligence checks available for Premium users.

Be the first to know about important CLDI news, forecast changes, insider trades & much more!

CLDI News

Valuation

CLDI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.78x
Industry
11.7x
Market
31.32x

CLDI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-68.99x
Industry
5.42x

CLDI's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
CLDI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLDI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$18.6M
Liabilities
$19.7M
Debt to equity
-17.99
CLDI's short-term assets ($11.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLDI's short-term assets ($11.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLDI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLDI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$13.5M
Investing
-$63.0k
Financing
$21.6M
CLDI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CLDI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CLDI$75.48M-8.19%-0.78x-68.99x
BCTX$75.43M-3.63%-3.63x-19.97x
ATHA$74.97M+5.35%-0.62x0.48x
CTCX$74.78M+2.86%N/A3.58x
BCAB$76.22M+2.58%-0.60x0.80x

Calidi Biotherapeutics Stock FAQ

What is Calidi Biotherapeutics's quote symbol?

(NYSEMKT: CLDI) Calidi Biotherapeutics trades on the NYSEMKT under the ticker symbol CLDI. Calidi Biotherapeutics stock quotes can also be displayed as NYSEMKT: CLDI.

If you're new to stock investing, here's how to buy Calidi Biotherapeutics stock.

What is the 52 week high and low for Calidi Biotherapeutics (NYSEMKT: CLDI)?

(NYSEMKT: CLDI) Calidi Biotherapeutics's 52-week high was $13.79, and its 52-week low was $1.50. It is currently -84.55% from its 52-week high and 42% from its 52-week low.

How much is Calidi Biotherapeutics stock worth today?

(NYSEMKT: CLDI) Calidi Biotherapeutics currently has 35,436,381 outstanding shares. With Calidi Biotherapeutics stock trading at $2.13 per share, the total value of Calidi Biotherapeutics stock (market capitalization) is $75.48M.

Calidi Biotherapeutics stock was originally listed at a price of $9.94 in Sep 10, 2021. If you had invested in Calidi Biotherapeutics stock at $9.94, your return over the last 2 years would have been -78.57%, for an annualized return of -53.71% (not including any dividends or dividend reinvestments).

How much is Calidi Biotherapeutics's stock price per share?

(NYSEMKT: CLDI) Calidi Biotherapeutics stock price per share is $2.13 today (as of Dec 8, 2023).

What is Calidi Biotherapeutics's Market Cap?

(NYSEMKT: CLDI) Calidi Biotherapeutics's market cap is $75.48M, as of Dec 11, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Calidi Biotherapeutics's market cap is calculated by multiplying CLDI's current stock price of $2.13 by CLDI's total outstanding shares of 35,436,381.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.